Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Drug Profile

Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Alternative Names: Adipose-derived mesenchymal progenitor cell therapy - Cellular Biomedicine Group; haMPC; MPC; ReJoin®

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellular Biomedicine Group; Shanghai Jiao Tong University
  • Class Antiasthmatics; Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cartilage disorders; Osteoarthritis
  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Mar 2017 Cellular Biomedicine terminates phase II trial in Cartilage disorders in China before March 2017 due to difficulty of getting patients back for a second arthroscopic examination
  • 01 Nov 2016 Cellular Biomedicine completes a phase IIb trial for Osteoarthritis in China (NCT02162693)
  • 12 Aug 2016 Autologous adipose-derived mesenchymal stem cell therapy is still in phase II trials for Osteoarthritis in China (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top